HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK, Jiří JARKOVSKÝ, Markéta BERANOVÁ, Pavel JANSKY, Michal SVOBODA, Iveta KŘEPELKOVÁ, Richard ROKYTA, Petr WIDIMSKY and Michal KARPISEK. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. JOURNAL OF PERSONALIZED MEDICINE. BASEL: MDPI, 2021, vol. 11, No 6, p. 1-12. ISSN 2075-4426. Available from: https://dx.doi.org/10.3390/jpm11060508.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty
Authors HROMADKA, Milan (203 Czech Republic), Zuzana MOTOVSKA (203 Czech Republic), Ota HLINOMAZ (203 Czech Republic, belonging to the institution), Petr KALA (203 Czech Republic, belonging to the institution), Frantisek TOUSEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Markéta BERANOVÁ (203 Czech Republic, belonging to the institution), Pavel JANSKY (203 Czech Republic), Michal SVOBODA (203 Czech Republic, belonging to the institution), Iveta KŘEPELKOVÁ (203 Czech Republic), Richard ROKYTA (203 Czech Republic), Petr WIDIMSKY (203 Czech Republic) and Michal KARPISEK (203 Czech Republic).
Edition JOURNAL OF PERSONALIZED MEDICINE, BASEL, MDPI, 2021, 2075-4426.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30218 General and internal medicine
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.508
RIV identification code RIV/00216224:14110/21:00121971
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/jpm11060508
UT WoS 000666506600001
Keywords in English acute myocardial infarction; risk stratification; microRNA; miR-126-3P; miR-223-3p; antithrombotic therapy individualization
Tags 14110115, 14110211, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/7/2023 12:58.
Abstract
Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.
PrintDisplayed: 23/7/2024 07:21